Gensight Biologics Liabilities 2024

Gensight Biologics Aktienanalyse

What does Gensight Biologics do?

Gensight Biologics SA is a biotechnology company specializing in the development of gene therapies for genetically inherited eye diseases. The company is based in Paris, France, with offices in Amsterdam and New York. The company's history began in 2012 when the founder, Bernard Gilly, had the idea to develop gene therapy for liver diseases. After several years of research and development, it became clear that the company could not develop a commercially viable solution due to the complexity of liver diseases and the high treatment costs. In 2013, the company shifted its focus to the development of gene therapies for genetically inherited eye diseases. Since then, Gensight Biologics SA has conducted several studies and clinical trials and is now a leading provider in this market segment. Gensight Biologics SA's business model is based on the development of gene therapies aimed at correcting the genetic defect and repairing the corresponding cells in the eye. The gene therapy is conducted using adeno-associated viruses (AAV), which introduce a normal gene into the diseased tissue. Gensight Biologics' particular focus is on the development of gene therapies for the treatment of eye diseases, with a focus on the research and treatment of rare diseases. The company has two central product lines. Firstly, it offers gene therapies targeting genetically inherited eye diseases such as retinitis pigmentosa (RP). This disease is inherited and leads to gradual loss of vision and, in severe cases, blindness. Gene therapy aims to repair the responsible gene and improve cell function and vision. Secondly, Gensight Biologics SA offers gene therapies targeting liver diseases such as Wilson's disease and gout, where copper and uric acid, respectively, are not properly metabolized. Here, gene therapy aims to repair the corresponding gene and reduce disease-related functional impairments. Gensight Biologics SA works closely with regulatory authorities and clinical partners to ensure the safety and efficacy of their gene therapies. The therapies are currently being tested in clinical trials to assess their effectiveness and safety. Gensight Biologics SA also collaborates with some of the world's leading doctors and researchers in the field of ophthalmology. While Gensight Biologics SA's gene therapies are still in the development phase, the clinical trials have shown promising results, and the company expects their therapies to be approved soon. The company follows a well-thought-out growth model and plans to develop further products for the treatment of eye diseases in the future. Overall, Gensight Biologics SA is a biotechnology company specialized in gene therapies, with a focus on researching and treating rare eye diseases. The company presents a promising investment option due to its innovative product range, close collaboration with researchers and clinical partners, and solid growth strategy. Gensight Biologics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Liabilities Details

Assessing Gensight Biologics's Liabilities

Gensight Biologics's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Gensight Biologics's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Gensight Biologics's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Gensight Biologics's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Gensight Biologics’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Gensight Biologics stock

What is the level of liabilities of Gensight Biologics this year?

Gensight Biologics has a debt balance of 39.83 M EUR this year.

What were the liabilities of Gensight Biologics compared to the previous year?

The liabilities of Gensight Biologics have increased by -3.36% dropped compared to the previous year.

What are the consequences of high debt for investors of Gensight Biologics?

High liabilities can pose a risk for investors of Gensight Biologics, as they can weaken the company's financial position and impair its ability to meet its obligations.

What consequences do low liabilities have for investors in Gensight Biologics?

Low liabilities mean that Gensight Biologics has a strong financial position and is able to meet its obligations without overburdening its finances.

How does an increase in liabilities of Gensight Biologics affect the company?

An increase in liabilities of Gensight Biologics can lead to the company having more obligations and potentially find it more difficult to meet its financial commitments.

How does a reduction in the liabilities of Gensight Biologics affect the company?

A decrease in the liabilities of Gensight Biologics can lead to the company having fewer obligations and a stronger financial position, which can make it easier for the company to fulfill its financial commitments.

What are some factors that influence the liabilities of Gensight Biologics?

Some factors that can influence the liabilities of Gensight Biologics include investments, acquisitions, operating costs, and sales development.

Why is the level of liabilities of Gensight Biologics so important for investors?

The liabilities of Gensight Biologics are important for investors as they serve as an indicator of the company's financial stability and provide investors with information on how the company meets its financial obligations.

What strategic measures can Gensight Biologics take to modify the liabilities?

To change its liabilities, Gensight Biologics can take measures such as cost savings, increasing revenue, selling assets, raising investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to choose the best strategic actions.

How much dividend does Gensight Biologics pay?

Over the past 12 months, Gensight Biologics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Gensight Biologics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Gensight Biologics?

The current dividend yield of Gensight Biologics is .

When does Gensight Biologics pay dividends?

Gensight Biologics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Gensight Biologics?

Gensight Biologics paid dividends every year for the past 0 years.

What is the dividend of Gensight Biologics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Gensight Biologics located?

Gensight Biologics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Gensight Biologics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Gensight Biologics from 9/29/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 9/29/2024.

When did Gensight Biologics pay the last dividend?

The last dividend was paid out on 9/29/2024.

What was the dividend of Gensight Biologics in the year 2023?

In the year 2023, Gensight Biologics distributed 0 EUR as dividends.

In which currency does Gensight Biologics pay out the dividend?

The dividends of Gensight Biologics are distributed in EUR.